State of Alaska Department of Revenue Raises Holdings in Azenta, Inc. $AZTA

State of Alaska Department of Revenue grew its position in shares of Azenta, Inc. (NASDAQ:AZTA) by 7.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,238 shares of the company’s stock after buying an additional 1,918 shares during the period. State of Alaska Department of Revenue owned 0.06% of Azenta worth $838,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in AZTA. Farther Finance Advisors LLC lifted its position in shares of Azenta by 788.1% during the 1st quarter. Farther Finance Advisors LLC now owns 968 shares of the company’s stock valued at $33,000 after buying an additional 859 shares during the last quarter. State of Wyoming lifted its position in shares of Azenta by 77.1% during the 1st quarter. State of Wyoming now owns 2,343 shares of the company’s stock valued at $81,000 after buying an additional 1,020 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its position in shares of Azenta by 13,184.2% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,524 shares of the company’s stock valued at $87,000 after buying an additional 2,505 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Azenta by 83.6% during the 2nd quarter. GAMMA Investing LLC now owns 3,446 shares of the company’s stock valued at $106,000 after buying an additional 1,569 shares during the last quarter. Finally, Quarry LP lifted its position in shares of Azenta by 41.5% during the 1st quarter. Quarry LP now owns 3,120 shares of the company’s stock valued at $108,000 after buying an additional 915 shares during the last quarter. Hedge funds and other institutional investors own 99.08% of the company’s stock.

Analysts Set New Price Targets

AZTA has been the topic of a number of recent research reports. Evercore ISI set a $33.00 price target on Azenta and gave the company an “in-line” rating in a research report on Tuesday, August 5th. Raymond James Financial raised Azenta from a “market perform” rating to an “outperform” rating and set a $35.00 price target on the stock in a research report on Wednesday, August 6th. Stephens assumed coverage on Azenta in a research note on Tuesday, July 22nd. They set an “equal weight” rating and a $35.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Azenta in a research note on Saturday, September 27th. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Azenta presently has an average rating of “Hold” and a consensus target price of $35.75.

Azenta Stock Performance

NASDAQ:AZTA opened at $31.80 on Tuesday. Azenta, Inc. has a 52-week low of $23.91 and a 52-week high of $55.63. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of -13.14 and a beta of 1.62. The business’s fifty day moving average is $30.35 and its 200 day moving average is $29.87.

Azenta (NASDAQ:AZTA) last announced its earnings results on Tuesday, August 5th. The company reported $0.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. The business had revenue of $143.94 million for the quarter, compared to analyst estimates of $149.64 million. Azenta had a positive return on equity of 1.35% and a negative net margin of 18.45%.The company’s quarterly revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.14 EPS. Equities analysts predict that Azenta, Inc. will post 0.53 EPS for the current fiscal year.

About Azenta

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.